Page last updated: 2024-10-29

isoniazid and HIV

isoniazid has been researched along with HIV in 50 studies

Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).

HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.

Research Excerpts

ExcerptRelevanceReference
"In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to the 6-month control regimen and was safe."9.69Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). ( Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z, 2023)
"International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1078, a randomized noninferiority study designed to compare the safety of starting isoniazid preventive therapy (IPT) in women living with human immunodeficiency virus (HIV) either during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not individual outcomes."9.41Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus. ( Aaron, L; Chakhtoura, N; Chipato, T; Gupta, A; Jean-Philippe, P; Lespinasse, D; Loftis, AJ; Masheto, G; McCarthy, K; Montepiedra, G; Nematadzira, T; Ngocho, J; Nyati, M; Onyango-Makumbi, C; Patil, S; Theron, G; Tongprasert, F; Weinberg, A; Zimmer, B, 2021)
"Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV."9.27Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. ( Bisson, GP; Gupta, A; Hosseinipour, MC; Hughes, MD; Kidonge, KK; Kumwenda, J; Lavenberg, JA; Miyahara, S; Ngongondo, M; Nyirenda, M; Sun, X; Torres, TS, 2018)
"Isoniazid did not reduce the incidence of TB in CLHIV."8.98Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. ( Charan, J; Emmanuel, P; Goyal, JP; Kumar, A; Patel, A; Reljic, T, 2018)
"Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI)."8.31High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. ( Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y, 2023)
"Rifampin appears to be safe and as effective as isoniazid across many populations with health conditions, including HIV."8.02Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. ( Al-Jahdali, H; Bah, B; Belo, M; Campbell, JR; Cook, VJ; Long, R; Menzies, D; Schwartzman, K; Trajman, A, 2021)
"Isoniazid preventive therapy (IPT) against tuberculosis (TB) is a life-saving intervention for people living with HIV (PLHIV)."8.02Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). ( Auld, AF; Gunde, LJ; Jahn, A; Kirking, HL; Maida, A; Nabity, SA; Nyirenda, RK; Odo, M; Oeltmann, JE; Shiraishi, RW; Surie, D, 2021)
"Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children."7.88Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018)
"Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited."7.81Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015)
"Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of isoniazid preventive therapy (IPT)."7.77Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. ( Cohen, T; Jenkins, HE; Zignol, M, 2011)
"As part of a research directed to the synthesis of novel isoniazid derivatives with potential activity on mycobacteria and HIV virus, the acetophenone-isonicotinoylhydrazones 3 and the 4-aryl-1-methoxy-1-(4-pyridyl)- 2,3-diaza-1,3-butadienes 5, obtained by reaction between isonicotinoylhydrazones and diazomethane, have been prepared and tested for such activities."7.69Halogenated isoniazid derivatives as possible antimycobacterial and anti-HIV agents--III. ( Gabbrielli, G; Maccari, R; Ottanà, R; Pizzimenti, FC; Vigorita, MG; Zappalà, C, 1994)
"Cumulative 24-month Mycobacterium tuberculosis infection incidence (measured primarily by tuberculin skin test [TST]) was high among human immunodeficiency virus exposed but uninfected infants (8."7.11Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial. ( Carimo, N; Cranmer, LM; Escudero, JN; Hawn, TR; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Mecha, J; Richardson, BA; Warr, AJ, 2022)
"In LBW/preterm infants, INH dosing needs frequent adjustment to account for growth and maturation."5.72Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. ( Bekker, A; Béranger, A; Browning, R; Cababasay, M; Capparelli, EV; Cotton, MF; Mirochnick, M; Moye, J; Savic, RM; Solans, BP; Violari, A; Wang, J; Wiesner, L, 2022)
"In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to the 6-month control regimen and was safe."5.69Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). ( Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z, 2023)
" We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol."5.41Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. ( Béranger, A; Gegia, M; Linh, NN; Mirzayev, F; Mohamed, A; Nahid, P; Radtke, K; Savic, RM; Schumacher, SG; Solans, BP, 2023)
"International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1078, a randomized noninferiority study designed to compare the safety of starting isoniazid preventive therapy (IPT) in women living with human immunodeficiency virus (HIV) either during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not individual outcomes."5.41Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus. ( Aaron, L; Chakhtoura, N; Chipato, T; Gupta, A; Jean-Philippe, P; Lespinasse, D; Loftis, AJ; Masheto, G; McCarthy, K; Montepiedra, G; Nematadzira, T; Ngocho, J; Nyati, M; Onyango-Makumbi, C; Patil, S; Theron, G; Tongprasert, F; Weinberg, A; Zimmer, B, 2021)
"Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs."5.32Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. ( Amofa, J; Driver, CR; Fujiwara, PI; Gourevitch, MN; Highley, E; Kaye, K; Munsiff, SS; Rubino, MA; Scholten, JN; Seewald, R; Trim, C, 2003)
"Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV."5.27Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. ( Bisson, GP; Gupta, A; Hosseinipour, MC; Hughes, MD; Kidonge, KK; Kumwenda, J; Lavenberg, JA; Miyahara, S; Ngongondo, M; Nyirenda, M; Sun, X; Torres, TS, 2018)
"South African guidelines recommend protease-inhibitor-based antiretroviral therapy (ART) with lopinavir-ritonavir for human immunodeficiency virus (HIV)-infected children <36 months of age."5.14Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. ( Abrams, EJ; Coovadia, A; Ko, S; Kuhn, L; Meyers, T; Reitz, C; Sherman, G; Strehlau, R, 2010)
"Although isoniazid (INH) preventive therapy (IPT) can reduce the risk of active TB among HIV-infected individuals, preventive therapy is rarely used in developing countries."5.11INH preventive therapy among adult HIV-infected patients in Thailand. ( Hiransuthikul, N; Hiransuthikul, P; Nelson, KE; Paewplot, R; Vorayingyong, A, 2005)
"Isoniazid did not reduce the incidence of TB in CLHIV."4.98Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. ( Charan, J; Emmanuel, P; Goyal, JP; Kumar, A; Patel, A; Reljic, T, 2018)
"Because treatment can only be initiated when infection is detected, and is guided by the results of antimicrobial susceptibility testing, there recently has been a marked increase in the development and testing of novel assays designed to detect Mycobacterium tuberculosis complex, with or without simultaneous detection of resistance to isoniazid and/or rifampin."4.89Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing. ( Wilson, ML, 2013)
"Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI)."4.31High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. ( Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y, 2023)
"We used nonlinear mixed-effects modeling to characterize the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide, and investigated the association of human immunodeficiency virus (HIV), antiretroviral therapy (ART), drug formulation, age, and body size with their pharmacokinetics."4.31Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. ( Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H, 2023)
"Rifampin appears to be safe and as effective as isoniazid across many populations with health conditions, including HIV."4.02Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. ( Al-Jahdali, H; Bah, B; Belo, M; Campbell, JR; Cook, VJ; Long, R; Menzies, D; Schwartzman, K; Trajman, A, 2021)
"Isoniazid preventive therapy (IPT) against tuberculosis (TB) is a life-saving intervention for people living with HIV (PLHIV)."4.02Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). ( Auld, AF; Gunde, LJ; Jahn, A; Kirking, HL; Maida, A; Nabity, SA; Nyirenda, RK; Odo, M; Oeltmann, JE; Shiraishi, RW; Surie, D, 2021)
"Isoniazid preventive therapy (IPT) is widely used to protect against tuberculosis (TB) in people living with human immunodeficiency virus (HIV)."3.96Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data. ( Boulle, A; Cohen, K; Davies, MA; de Waal, R; Heekes, A; Jacob, N; Kalk, E; Maartens, G; Mehta, U; Myer, L, 2020)
"31) were associated with increased risk of tuberculosis whereas taking Isoniazid Preventive Therapy (IPT) (AHR = 0."3.96Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study. ( Aemro, A; Anlay, DZ; Jember, A, 2020)
" The secondary objective was to determine the overall incidence of hepatitis in children on Anti tubercular treatment (ATT) and isoniazid prophylactic therapy (IPT)."3.91Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children. ( Indumathi, CK; Jain, S; Krishnamurthy, S; Sethuraman, A, 2019)
"Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children."3.88Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018)
"Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited."3.81Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015)
"Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of isoniazid preventive therapy (IPT)."3.77Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. ( Cohen, T; Jenkins, HE; Zignol, M, 2011)
"Cumulative 24-month Mycobacterium tuberculosis infection incidence (measured primarily by tuberculin skin test [TST]) was high among human immunodeficiency virus exposed but uninfected infants (8."3.11Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial. ( Carimo, N; Cranmer, LM; Escudero, JN; Hawn, TR; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Mecha, J; Richardson, BA; Warr, AJ, 2022)
"There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ."2.82Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ( Bekker, A; Donald, PR; Draper, HR; Hesseling, AC; McIlleron, HM; Murray, S; Schaaf, HS; van der Laan, L; Wiesner, L, 2016)
"In LBW/preterm infants, INH dosing needs frequent adjustment to account for growth and maturation."1.72Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. ( Bekker, A; Béranger, A; Browning, R; Cababasay, M; Capparelli, EV; Cotton, MF; Mirochnick, M; Moye, J; Savic, RM; Solans, BP; Violari, A; Wang, J; Wiesner, L, 2022)
"The frequency of late recurrences following treatment completion has not been well-studied."1.37When tuberculosis comes back: who develops recurrent tuberculosis in california? ( Deriemer, K; Flood, JM; Pascopella, L; Watt, JP, 2011)
"Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs."1.32Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. ( Amofa, J; Driver, CR; Fujiwara, PI; Gourevitch, MN; Highley, E; Kaye, K; Munsiff, SS; Rubino, MA; Scholten, JN; Seewald, R; Trim, C, 2003)

Research

Studies (50)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (2.00)18.2507
2000's5 (10.00)29.6817
2010's27 (54.00)24.3611
2020's17 (34.00)2.80

Authors

AuthorsStudies
Banerjee, D1
Yogeeswari, P1
Bhat, P1
Thomas, A1
Srividya, M1
Sriram, D1
Béranger, A2
Bekker, A2
Solans, BP2
Cotton, MF4
Mirochnick, M1
Violari, A2
Wang, J1
Cababasay, M1
Wiesner, L4
Browning, R1
Moye, J1
Capparelli, EV1
Savic, RM3
LaCourse, SM3
Escudero, JN3
Mecha, J2
Warr, AJ3
Richardson, BA3
Carimo, N1
Cranmer, LM3
Maleche-Obimbo, E3
Matemo, D3
Kinuthia, J3
Hawn, TR3
John-Stewart, G2
Pettit, AC1
Phillips, PPJ1
Kurbatova, E1
Vernon, A1
Nahid, P2
Dawson, R1
Dooley, KE3
Sanne, I1
Waja, Z2
Mohapi, L2
Podany, AT1
Samaneka, W1
Johnson, JL1
Muzanyi, G1
Lalloo, UG1
Bryant, K1
Sizemore, E1
Scott, N1
Dorman, SE1
Chaisson, RE4
Swindells, S2
Radtke, K1
Mohamed, A1
Mirzayev, F1
Gegia, M1
Linh, NN1
Schumacher, SG1
Jarrett, RT1
van der Heijden, Y1
Shotwell, MS1
Chihota, V1
Marzinke, MA1
Churchyard, GJ1
Sekayi, W1
Namyalo, E1
Namayanja, J1
Kungu, JM1
Galileya, LT1
Wasmann, RE1
Chabala, C1
Rabie, H1
Lee, J1
Njahira Mukui, I1
Hesseling, A1
Zar, H1
Aarnoutse, R1
Turkova, A1
Gibb, D1
McIlleron, H3
Denti, P3
Stout, JE1
Sterling, TR1
Horsburgh, CR1
Ramchandani, R1
Salazar-Austin, N1
Cohn, S1
Lala, S1
Hoffmann, CJ1
Martinson, N1
Kalk, E1
Heekes, A1
Mehta, U1
de Waal, R1
Jacob, N1
Cohen, K1
Myer, L1
Davies, MA1
Maartens, G2
Boulle, A2
Schutz, C1
Chirehwa, M1
Barr, D1
Ward, A1
Janssen, S2
Burton, R1
Wilkinson, RJ1
Shey, M1
Meintjes, G2
John-Stewart, GC1
Aemro, A1
Jember, A1
Anlay, DZ1
Campbell, JR1
Al-Jahdali, H1
Bah, B1
Belo, M1
Cook, VJ1
Long, R1
Schwartzman, K1
Trajman, A1
Menzies, D1
Theron, G1
Montepiedra, G1
Aaron, L1
McCarthy, K1
Chakhtoura, N1
Jean-Philippe, P1
Zimmer, B1
Loftis, AJ1
Chipato, T1
Nematadzira, T1
Nyati, M1
Onyango-Makumbi, C1
Masheto, G1
Ngocho, J1
Tongprasert, F1
Patil, S1
Lespinasse, D1
Weinberg, A1
Gupta, A3
Nabity, SA1
Gunde, LJ1
Surie, D1
Shiraishi, RW1
Kirking, HL1
Maida, A1
Auld, AF1
Odo, M1
Jahn, A1
Nyirenda, RK1
Oeltmann, JE1
Krishnan, S1
Queiroz, ATL1
Gupte, N1
Bisson, GP2
Kumwenda, J2
Naidoo, K1
Mave, V1
Mngqibisa, R1
Lama, JR1
Hosseinipour, MC2
Andrade, BB1
Karakousis, PC1
Tashiro, K1
Horita, N1
Nagai, K1
Ikeda, M1
Shinkai, M1
Yamamoto, M1
Sato, T1
Hara, Y1
Nagakura, H1
Shibata, Y1
Watanabe, H1
Nakashima, K1
Ushio, R1
Nagashima, A1
Narita, A1
Kobayashi, N1
Kudo, M1
Kaneko, T1
van der Laan, LE1
Garcia-Prats, AJ1
Schaaf, HS4
Tikiso, T1
de Kock, M1
Winckler, J1
Norman, J1
Hesseling, AC3
Charan, J1
Goyal, JP1
Reljic, T1
Emmanuel, P1
Patel, A1
Kumar, A1
Ngongondo, M1
Miyahara, S1
Hughes, MD1
Sun, X1
Lavenberg, JA1
Torres, TS1
Nyirenda, M1
Kidonge, KK1
Pasipanodya, JG1
Gumbo, T1
Baker, BJ1
Zhao, Y1
Fox, T1
Manning, K1
Stewart, A1
Tiffin, N1
Khomo, N1
Leslie, J1
Mudaly, V1
Kock, Y1
Wasserman, S1
Alffenaar, JC1
Heysell, SK1
Mpagama, SG1
Indumathi, CK1
Sethuraman, A1
Jain, S1
Krishnamurthy, S1
Walsh, KF1
Souroutzidis, A1
Vilbrun, SC1
Peeples, M1
Joissaint, G1
Delva, S1
Widmann, P1
Royal, G1
Pry, J1
Bang, H1
Pape, JW1
Koenig, SP1
Gezae, KE1
Abebe, HT1
Gebretsadik, LG1
Saunders, MJ1
Evans, CA1
Wilson, ML1
van Griensven, J1
Choun, K1
Chim, B1
Thai, S1
Lorent, N1
Lynen, L1
Ayele, HT1
Mourik, MS1
Debray, TP1
Bonten, MJ1
Draper, HR1
van der Laan, L1
Murray, S1
Donald, PR1
McIlleron, HM1
Bélard, S1
Remppis, J1
Bootsma, S1
Kombila, DU1
Beyeme, JO1
Rossatanga, EG1
Kokou, C1
Osbak, KK1
Obiang Mba, RM1
Kaba, HM1
Traoré, AN1
Ehrhardt, J1
Bache, EB1
Flamen, A1
Rüsch-Gerdes, S1
Frank, M1
Adegnika, AA1
Lell, B1
Niemann, S1
Kremsner, PG1
Loembé, MM1
Alabi, AS1
Grobusch, MP1
Aung, NM1
Hanson, J1
Kyi, TT1
Htet, ZW1
Cooper, DA1
Boyd, MA1
Kyi, MM1
Saw, HA1
Munseri, PJ1
Talbot, EA1
Mtei, L1
Fordham von Reyn, C1
Reitz, C1
Coovadia, A1
Ko, S1
Meyers, T1
Strehlau, R1
Sherman, G1
Kuhn, L1
Abrams, EJ1
Cohen, T2
Murray, M1
Wallengren, K1
Alvarez, GG1
Samuel, EY1
Wilson, D1
Jenkins, HE1
Zignol, M1
Pascopella, L1
Deriemer, K1
Watt, JP1
Flood, JM1
Kim, S1
Madhi, S1
Nachman, S1
Victor, TC1
McSherry, G1
Mitchell, C1
Shaweno, D1
Worku, A1
Scholten, JN1
Driver, CR1
Munsiff, SS1
Kaye, K1
Rubino, MA1
Gourevitch, MN1
Trim, C1
Amofa, J1
Seewald, R1
Highley, E1
Fujiwara, PI1
Hiransuthikul, N1
Nelson, KE1
Hiransuthikul, P1
Vorayingyong, A1
Paewplot, R1
Vigorita, MG1
Ottanà, R1
Zappalà, C1
Maccari, R1
Pizzimenti, FC1
Gabbrielli, G1
Gie, RP1
van Rie, A1
Seifart, HI1
van Helden, PD1
Mac-Arthur, A1
Gloyd, S1
Perdigão, P1
Noya, A1
Sacarlal, J1
Kreiss, J1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants[NCT02613169]Phase 2300 participants (Actual)Interventional2016-08-31Completed
A Randomized Trial to Compare Effectiveness of 4 Months Rifampin (4 RIF) With 9 Months Isoniazid (9 INH) in the Prevention of Active TB in Children: The P4v9 Trial[NCT00170209]Phase 3844 participants (Actual)Interventional2011-08-31Completed
A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness[NCT00931736]Phase 36,031 participants (Actual)Interventional2009-08-31Completed
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299]Phase 4302 participants (Actual)Interventional2017-04-07Completed
Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)[NCT01637558]Phase 4200 participants (Actual)Interventional2012-11-30Completed
A Pilot Study to Evaluate Video Observed Treatment Among Tuberculosis Patients From Lambaréné Using an Instant Messenger Application[NCT05865626]30 participants (Actual)Interventional2018-10-10Completed
DARDAR Health Project (Disseminated Tuberculosis and HIV Infection)[NCT00052195]Phase 2/Phase 31,975 participants (Actual)Interventional2001-09-30Completed
A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177]Phase 496 participants (Actual)Interventional2013-01-31Completed
Z 31411 - The Effect of Xpert MTB/RIF on Patient Health Outcomes and Empirical TB Treatment Among Persons Living With HIV/AIDS: A Parallel-Group Prospective Cohort Study Under Real-World Conditions in Lusaka, Zambia[NCT02729532]776 participants (Actual)Observational2016-06-22Completed
Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056]360 participants (Anticipated)Interventional2023-02-28Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Combined Outcome of MTB Infection, TB Disease, and Death

"Number of infants with a combined endpoint of MTB infection, TB disease, and death~MTB infection as measured by IGRA or tuberculin skin test at 12 months post-enrollment~TB disease including microbiologically confirmed (culture or Xpert positive), or probable TB (clinical diagnosis).~Death of infant" (NCT02613169)
Timeframe: Over 12 months after randomization

InterventionParticipants (Count of Participants)
Isoniazid11
No Isoniazid19

Mycobacterium Tuberculosis (MTB) Infection

Among HEU infants enrolled at approximately 6 weeks of age, compare the risk of acquiring MTB infection during 1 year of follow-up in infants randomized to receive INH vs. no INH using an interferon-gamma release (IGRA) QuantiFERON-TB Gold Plus (QFT-Plus) assay or tuberculin skin test as part of a composite endpoint to determine MTB infection status (NCT02613169)
Timeframe: at 12 months post randomization

Interventionparticipants (Number)
Isoniazid10
No Isoniazid18

Mycobacterium Tuberculosis (MTB) Infection Cumulative Incidence

Among HEU infants enrolled at approximately 6 weeks of age, compare the risk of acquiring MTB infection during 1 year of follow-up in infants randomized to receive INH vs. no INH using an interferon-gamma release (IGRA) QuantiFERON-TB Gold Plus (QFT-Plus) assay or tuberculin skin test as part of a composite endpoint to determine MTB infection status (NCT02613169)
Timeframe: at 12 months post randomization

InterventionTB infections/100 person years (Number)
Isoniazid7.0
No Isoniazid13.4

Severe Adverse Events (SAE)

Number of infants with grade 3 or higher treatment-related adverse events as assessed by DAIDS Table for the Grading Severity of Pediatric Adverse Experiences (NCT02613169)
Timeframe: Over 12 months after randomization

InterventionParticipants (Count of Participants)
Isoniazid21
No Isoniazid16

Cumulative Incidence of Participants Experiencing a Grade 3/4 Hepatotoxicity

Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

Interventionpercent (Number)
INH and Vitamin B68.3

Number of Participants Who Discontinued Treatment

Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

InterventionParticipants (Count of Participants)
INH and Vitamin B632

Number of Participants With Alanine Transaminase (ALT) or Aspartate Transaminase (AST) Elevations at Study Screening

Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit

InterventionParticipants (Count of Participants)
Study Screening80

Number of Participants With Latent Tuberculosis at Study Screening.

Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit

InterventionParticipants (Count of Participants)
Study Screening308

INH Concentration in Hair: (INH Pmol + Acetyl INH Pmol) Per mg of Hair

INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation

Interventionpmol/mg (Median)
at 3 monthsat 6 months
INH and Vitamin B636.037.8

Percentage of Participants With Suboptimal INH Medication Adherence

Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)

Interventionpercentage of participants (Number)
at 3 monthsat 6 months
INH and Vitamin B631.343.9

Self-reported INH Medication Adherence: Number of Days Taking INH in the Past 30 Days

"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH

Interventiondays (Median)
at 3 monthsat 6 months
INH and Vitamin B63030

Self-reported INH Medication Adherence by the Self Rating Single Item (SRSI) Scale

The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH

InterventionParticipants (Count of Participants)
At 3 months72558043At 6 months72558043
ExcellentVery goodGoodFairPoorVery poor
INH and Vitamin B6160
INH and Vitamin B679
INH and Vitamin B638
INH and Vitamin B62
INH and Vitamin B6124
INH and Vitamin B690
INH and Vitamin B641
INH and Vitamin B64
INH and Vitamin B60
INH and Vitamin B61

Reviews

4 reviews available for isoniazid and HIV

ArticleYear
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 05-03, Volume: 76, Issue:9

    Topics: Adolescent; Adult; Antitubercular Agents; Child; Ethambutol; HIV; HIV Infections; Humans; Isoniazid;

2023
Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis.
    The Pediatric infectious disease journal, 2018, Volume: 37, Issue:8

    Topics: Antitubercular Agents; Child; HIV; HIV Infections; Humans; Isoniazid; Randomized Controlled Trials a

2018
Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing.
    Archives of pathology & laboratory medicine, 2013, Volume: 137, Issue:6

    Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; Coinfection;

2013
Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Antitubercular Agents; HIV; HIV Infections; Humans; Isoniazid; Randomized Controlled Trials as Topic

2015

Trials

13 trials available for isoniazid and HIV

ArticleYear
Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 12-19, Volume: 75, Issue:12

    Topics: Antitubercular Agents; Child, Preschool; Follow-Up Studies; HIV; HIV Infections; Humans; Incidence;

2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3

    Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxac

2023
Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent
    BMJ open, 2020, 01-21, Volume: 10, Issue:1

    Topics: Antitubercular Agents; Female; HIV; HIV Infections; Humans; Incidence; Infant; Isoniazid; Kenya; Mal

2020
A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 07-15, Volume: 73, Issue:2

    Topics: Antitubercular Agents; HIV; HIV Infections; Humans; Infant; Isoniazid; Kenya; Mycobacterium tubercul

2021
Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 06-01, Volume: 72, Issue:11

    Topics: Adolescent; Child; Female; HIV; HIV Infections; Humans; Infant, Newborn; Isoniazid; Pregnancy; Pregn

2021
Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Biomark

2021
HbA1c level cannot predict the treatment outcome of smear-positive non-multi-drug-resistant HIV-negative pulmonary tuberculosis inpatients.
    Scientific reports, 2017, 04-13, Volume: 7

    Topics: Adult; Aged; Aged, 80 and over; Female; Glycated Hemoglobin; HIV; Humans; Isoniazid; Male; Middle Ag

2017
Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
    Journal of acquired immune deficiency syndromes (1999), 2018, 05-01, Volume: 78, Issue:1

    Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antitubercular Agents; Aspartate Aminotransfera

2018
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:4

    Topics: Anti-Bacterial Agents; Area Under Curve; Coinfection; Drug Dosage Calculations; Ethambutol; Female;

2016
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2008, Volume: 12, Issue:9

    Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi

2008
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2008, Volume: 12, Issue:9

    Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi

2008
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2008, Volume: 12, Issue:9

    Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi

2008
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2008, Volume: 12, Issue:9

    Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi

2008
Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.
    The Journal of infectious diseases, 2010, Apr-15, Volume: 201, Issue:8

    Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Child, Preschool; Drug Therapy, Combin

2010
High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2012, Volume: 16, Issue:2

    Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double

2012
INH preventive therapy among adult HIV-infected patients in Thailand.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2005, Volume: 9, Issue:3

    Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Female; Follow

2005

Other Studies

33 other studies available for isoniazid and HIV

ArticleYear
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:1

    Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; I

2011
Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-29, Volume: 75, Issue:6

    Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Child, Preschool; Genotype; HIV; HIV Infection

2022
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
    Antimicrobial agents and chemotherapy, 2023, 02-16, Volume: 67, Issue:2

    Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Weight; Drug Therapy, Combination;

2023
Prevalence and predictors of tuberculosis among HIV patients who completed isoniazid preventive therapy (IPT) at Reach out Mbuya community health initiative.
    Scientific reports, 2023, 10-16, Volume: 13, Issue:1

    Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; HIV; HIV Infections; HIV Seropositivity; Huma

2023
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
    PLoS medicine, 2023, Volume: 20, Issue:11

    Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Huma

2023
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
    The New England journal of medicine, 2019, 09-12, Volume: 381, Issue:11

    Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis

2019
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply.
    The New England journal of medicine, 2019, 09-12, Volume: 381, Issue:11

    Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis

2019
Isoniazid Preventive Therapy and Pregnancy Outcomes in Women Living With Human Immunodeficiency Virus in the Tshepiso Cohort.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 09-12, Volume: 71, Issue:6

    Topics: Antitubercular Agents; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Preg

2020
Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 11-05, Volume: 71, Issue:8

    Topics: Antitubercular Agents; Female; HIV; HIV Infections; Humans; Isoniazid; Pregnancy; Pregnant Women; So

2020
Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis.
    British journal of clinical pharmacology, 2020, Volume: 86, Issue:5

    Topics: Adult; Antitubercular Agents; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Tu

2020
Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study.
    BMC infectious diseases, 2020, Mar-26, Volume: 20, Issue:1

    Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Age

2020
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 11-02, Volume: 73, Issue:9

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid;

2021
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 11-02, Volume: 73, Issue:9

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid;

2021
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 11-02, Volume: 73, Issue:9

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid;

2021
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 11-02, Volume: 73, Issue:9

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid;

2021
Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).
    PloS one, 2021, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Ambulatory Care Facilities; Antitubercular Agents; Child; Child, Preschool; Femal

2021
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:2

    Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug

2018
Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 08-16, Volume: 67, Issue:5

    Topics: Antitubercular Agents; Coinfection; Drug Monitoring; HIV; HIV Infections; Humans; Isoniazid; Rifampi

2018
ART and lifelong IPT for health care workers with HIV: a priority for infection control.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2018, 04-01, Volume: 22, Issue:4

    Topics: Adolescent; Botswana; Health Personnel; HIV; Humans; Infection Control; Isoniazid; Middle Aged; Tube

2018
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 04-24, Volume: 68, Issue:9

    Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; E

2019
Therapeutic Drug Monitoring: The Need for Practical Guidance.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 03-05, Volume: 68, Issue:6

    Topics: Coinfection; Drug Monitoring; HIV; HIV Infections; Humans; Isoniazid; Rifampin; Sputum; Tuberculosis

2019
Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children.
    Indian journal of pediatrics, 2019, Volume: 86, Issue:3

    Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool;

2019
Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
    The American journal of tropical medicine and hygiene, 2019, Volume: 100, Issue:2

    Topics: Adult; Antitubercular Agents; Coinfection; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethiona

2019
Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009-2016: survival model approach.
    BMC infectious diseases, 2019, Feb-04, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Coinfection; Ethiopia; Female; HIV; HIV Infec

2019
Ending Tuberculosis through Prevention.
    The New England journal of medicine, 2019, 03-14, Volume: 380, Issue:11

    Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis

2019
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    Tropical medicine & international health : TM & IH, 2015, Volume: 20, Issue:12

    Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactio

2015
Tuberculosis Treatment Outcome and Drug Resistance in Lambaréné, Gabon: A Prospective Cohort Study.
    The American journal of tropical medicine and hygiene, 2016, Aug-03, Volume: 95, Issue:2

    Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Coinfection; Drug Resistance, Mul

2016
HIV care in Yangon, Myanmar; successes, challenges and implications for policy.
    AIDS research and therapy, 2017, Mar-04, Volume: 14, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Posit

2017
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
    PLoS medicine, 2010, Jun-22, Volume: 7, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte

2010
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
    PLoS medicine, 2010, Jun-22, Volume: 7, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte

2010
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
    PLoS medicine, 2010, Jun-22, Volume: 7, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte

2010
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
    PLoS medicine, 2010, Jun-22, Volume: 7, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte

2010
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009.
    PloS one, 2011, Volume: 6, Issue:7

    Topics: Adult; Antitubercular Agents; Comorbidity; Directly Observed Therapy; HIV; HIV Infections; Humans; I

2011
When tuberculosis comes back: who develops recurrent tuberculosis in california?
    PloS one, 2011, Volume: 6, Issue:11

    Topics: Adult; Antitubercular Agents; California; Drug Therapy, Combination; Female; HIV; HIV Infections; Hu

2011
Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study.
    BMC research notes, 2012, Dec-12, Volume: 5

    Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Drug Administration Schedule; Fem

2012
Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Dec-15, Volume: 37, Issue:12

    Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV; HIV Infectio

2003
Halogenated isoniazid derivatives as possible antimycobacterial and anti-HIV agents--III.
    Farmaco (Societa chimica italiana : 1989), 1994, Volume: 49, Issue:12

    Topics: Antiviral Agents; Cell Line; HIV; Hydrocarbons, Halogenated; Isoniazid; Microbial Sensitivity Tests;

1994
Second episode of tuberculosis in an HIV-infected child: relapse or reinfection?
    The Journal of infection, 2000, Volume: 41, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Amoxicillin-Potassium Clavulanate Combination; Antibiotics, A

2000
Characteristics of drug resistance and HIV among tuberculosis patients in Mozambique.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2001, Volume: 5, Issue:10

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antibiotics, Antitubercular; Child; Child, Pr

2001